Has anyone dealt with blood pressure reduction mechanisms on glp-1?

lisa_labSD said:

CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 7.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…

lisa_labSD said:

...cardiovascular risk is just another fad...

I understand the skepticism — we've all seen "miracle" weight loss solutions come and go. But consider what makes GLP-1 agonists different:

• Phase 3 RCTs with thousands of participants (not 20-person pilot studies)
• Published in NEJM, JAMA, Lancet (not press releases)
• Replicated across multiple independent research groups
• Proven cardiovascular and renal benefits beyond weight loss
• Biological mechanism fully characterized at the receptor level

This isn't a fad — it's a new drug class supported by the highest level of clinical evidence. The comparison to past fads is understandable but inappropriate.

lisa_labSD said:

CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 7.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…

I want to bring up the cardiovascular angle on cardiovascular risk.

The SELECT trial demonstrated a 20% reduction in MACE with semaglutide 2.4mg[1]. This is practice-changing because the CV benefit appears to be independent of the degree of weight loss — suggesting direct vascular and anti-inflammatory mechanisms.

For cardiovascular risk, this means we need to think beyond the primary outcome and consider the cardiovascular implications. The all-cause mortality reduction (HR 0.81) is the most clinically meaningful signal.

lisa_labSD said:

CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 7.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…

Bookmarking. The distinction being drawn above is the one nobody else makes.

Clinical perspective, offered as context rather than as advice.

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 13 months of treatment.

The 5 criteria (and my journey):

1. Waist circumference: 52" → 34" ✅ Resolved
2. Triglycerides: 248 → 118 ✅ Resolved
3. HDL: 36 → 60 ✅ Resolved
4. Blood pressure: 148/94 → 121/75 ✅ Resolved
5. Fasting glucose: 128 → 88 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

andrew_nyc said:

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 13 months of treatment.

Same pattern here, and in the same order.